Bachem Holding AG Asset Resilience Ratio

Latest as of December 2024: 0.00%

Bachem Holding AG asset resilience ratio. Bachem Holding AG (BANB) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Bachem Holding AG total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CHF0.00
≈ $0.00 USD Cash + Short-term Investments

Total Assets

CHF1.92 Billion
≈ $2.43 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Bachem Holding AG (2005–2024)

Asset resilience ratio of Bachem Holding AG from 2005 to 2024. This chart shows how Bachem Holding AG's Asset Resilience Ratio has changed over time. See Bachem Holding AG free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Bachem Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Bachem Holding AG's balance sheet.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CHF0.00 0%
Short-term Investments CHF0.00 0%
Total Liquid Assets CHF0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Bachem Holding AG maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Bachem Holding AG Industry Peers by Asset Resilience Ratio

Compare Bachem Holding AG's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 65.12%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.57%
Eupraxia Pharmaceuticals Inc
TO:EPRX
Biotechnology 25.13%
Cabio Biotech Wuhan Co Ltd
SHG:688089
Biotechnology 3.60%

Bachem Holding AG Asset Resilience Ratio by Year (2005–2024)

Bachem Holding AG asset resilience ratio by year from 2005 to 2024. The table below shows the annual Asset Resilience Ratio data for Bachem Holding AG.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.00% CHF0.00
≈ $0.00
CHF1.92 Billion
≈ $2.43 Billion
--
2023-12-31 8.37% CHF140.80 Million
≈ $178.01 Million
CHF1.68 Billion
≈ $2.13 Billion
-8.76pp
2022-12-31 17.12% CHF236.98 Million
≈ $299.60 Million
CHF1.38 Billion
≈ $1.75 Billion
-10.07pp
2021-12-31 27.20% CHF353.17 Million
≈ $446.50 Million
CHF1.30 Billion
≈ $1.64 Billion
+26.80pp
2013-12-31 0.40% CHF1.73 Million
≈ $2.19 Million
CHF438.78 Million
≈ $554.73 Million
-0.26pp
2008-12-31 0.66% CHF3.01 Million
≈ $3.80 Million
CHF457.32 Million
≈ $578.17 Million
-2.46pp
2007-12-31 3.12% CHF13.39 Million
≈ $16.93 Million
CHF429.07 Million
≈ $542.46 Million
-9.59pp
2006-12-31 12.71% CHF56.20 Million
≈ $71.05 Million
CHF442.24 Million
≈ $559.10 Million
+1.03pp
2005-12-31 11.68% CHF47.69 Million
≈ $60.29 Million
CHF408.21 Million
≈ $516.09 Million
--
pp = percentage points

About Bachem Holding AG

SW:BANB Switzerland Biotechnology
Market Cap
$7.99 Billion
CHF6.32 Billion CHF
Market Cap Rank
#3304 Global
#50 in Switzerland
Share Price
CHF84.35
Change (1 day)
+0.36%
52-Week Range
CHF48.72 - CHF86.00
All Time High
CHF165.41
About

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commerci… Read more